Literature DB >> 16985600

Preventing progression in men with mild symptoms of benign prostatic hyperplasia: a potential role for phytotherapy.

Yan Kit Fong, Sibylle Marihart, Mike Harik, Bob Djavan.   

Abstract

Prevalence of benign prostate hyperplasia (BPH) is increasing with the aging population worldwide. Throughout the 20th century, men with minimally symptomatic BPH were generally advised to defer treatment. Treatment deferral or watchful waiting has always appeared reasonable because mild lower urinary tract symptoms suggestive of bladder outlet obstruction are not bothersome and are often regarded as part of the aging process, progression is usually slow, and symptoms often regress spontaneously. This review examines the evidence of the natural history of BPH, highlighting the group of patients with mild symptoms, the risk factors for progression, and the potential role of phytotherapy in this group of men.

Entities:  

Year:  2004        PMID: 16985600      PMCID: PMC1472834     

Source DB:  PubMed          Journal:  Rev Urol        ISSN: 1523-6161


  39 in total

1.  Why patients use alternative medicine: results of a national study.

Authors:  J A Astin
Journal:  JAMA       Date:  1998-05-20       Impact factor: 56.272

2.  Prostate specific antigen predicts the long-term risk of prostate enlargement: results from the Baltimore Longitudinal Study of Aging.

Authors:  E James Wright; Junyong Fang; E Jeffrey Metter; Alan W Partin; Patricia Landis; Daniel W Chan; H Ballentine Carter
Journal:  J Urol       Date:  2002-06       Impact factor: 7.450

3.  High prevalence of benign prostatic hypertrophy in the community.

Authors:  W M Garraway; G N Collins; R J Lee
Journal:  Lancet       Date:  1991-08-24       Impact factor: 79.321

4.  Health-related quality of life associated with lower urinary tract symptoms in four countries.

Authors:  C J Girman; S J Jacobsen; T Tsukamoto; F Richard; W M Garraway; P P Sagnier; H A Guess; T Rhodes; P Boyle; M M Lieber
Journal:  Urology       Date:  1998-03       Impact factor: 2.649

5.  Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR long-term efficacy and safety study.

Authors:  C G Roehrborn; J McConnell; J Bonilla; S Rosenblatt; P B Hudson; G H Malek; P F Schellhammer; R Bruskewitz; A M Matsumoto; L H Harrison; H A Fuselier; P Walsh; J Roy; G Andriole; M Resnick; J Waldstreicher
Journal:  J Urol       Date:  2000-01       Impact factor: 7.450

6.  Quality-of-life impact of lower urinary tract symptom severity: results from the Health Professionals Follow-up Study.

Authors:  Garry Welch; Katie Weinger; Michael J Barry
Journal:  Urology       Date:  2002-02       Impact factor: 2.649

7.  Impact of previously unrecognized benign prostatic hyperplasia on the daily activities of middle-aged and elderly men.

Authors:  W M Garraway; E B Russell; R J Lee; G N Collins; G B McKelvie; M Hehir; A C Rogers; R J Simpson
Journal:  Br J Gen Pract       Date:  1993-08       Impact factor: 5.386

8.  Serenoa repens extract for benign prostate hyperplasia: a randomized controlled trial.

Authors:  K E Willetts; M S Clements; S Champion; S Ehsman; J A Eden
Journal:  BJU Int       Date:  2003-08       Impact factor: 5.588

9.  The natural history of untreated lower urinary tract symptoms in middle-aged and elderly men over a period of five years.

Authors:  A J Lee; W M Garraway; R J Simpson; W Fisher; D King
Journal:  Eur Urol       Date:  1998-10       Impact factor: 20.096

10.  The attitudes, behaviors and beliefs of patients of conventional vs. complementary (alternative) medicine.

Authors:  A Furnham; J Forey
Journal:  J Clin Psychol       Date:  1994-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.